| [1] |
ZHANG Yufeng, ZHANG Xinna, ZHOU Yanjiao.
PHLPP2 variation is associated with prognosis as well as ferroptosis in patients of advanced lung adenocarcinoma harboring EGFR+TP53 co-mutations
[J]. Basic & Clinical Medicine, 2026, 46(1): 103-108.
|
| [2] |
ZENG Cimei, HUANG Denggao, WANG Lei, LIANG Haimei, MA Ximiao.
Silencing LINC00460 inhibits proliferation and migration of human lung adenocarcinoma cell lines via EZH2
[J]. Basic & Clinical Medicine, 2025, 45(10): 1298-1305.
|
| [3] |
CHEN Qingxia, LIANG Yuling, LUO Yalan, NIU Bin.
Inhibition of NRF1/ABCC1 improves chemosensitivity of human lung adenocarcinoma cell lines to cisplatin
[J]. Basic & Clinical Medicine, 2025, 45(1): 51-59.
|
| [4] |
.
Association of seven antibody levels in lung cancer with chemotherapy effect and prognosis in patients with NSCLC
[J]. Basic & Clinical Medicine, 2024, 44(10): 1383-1387.
|
| [5] |
ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan.
Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549
[J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
|
| [6] |
CAO Chenxin, TANG Hui, GENG Ruixuan, GUO Fuping, BAI Chunmei, WANG Yingyi, LI Taisheng.
Correlation between circulating CD4+CD45RA+CD62L+ T cells and prognosis of metastatic non-small cell lung cancer treated with EGFR-TKI
[J]. Basic & Clinical Medicine, 2024, 44(5): 658-664.
|
| [7] |
LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang.
Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis
[J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
|
| [8] |
ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin.
Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib
[J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
|
| [9] |
ZHANG Zhenzhen, LI Yang, GAO Shengbao, XIA Dexin, YAN Yulan.
Recombinant Newcastle virus rL-RVG inhibits proliferation of human lung adenocarcinoma cell lines
[J]. Basic & Clinical Medicine, 2023, 43(10): 1549-1556.
|
| [10] |
ZHANG Jing, YANG Zigeng, WEI Hongmei, NING Haihong, XUE Xixi, JIN Ling, WU Bin.
Knockdown of prohibitin 2 promotes apoptosis in non-small cell lung cancer cell line A549
[J]. Basic & Clinical Medicine, 2023, 43(10): 1522-1529.
|
| [11] |
PAN Shan, LIN Kengqiang, CHEN Shuxing.
Pemetrexed inhibits the proliferation of lung adenocarcinoma cell line A549
[J]. Basic & Clinical Medicine, 2023, 43(9): 1359-1363.
|
| [12] |
YAN Chenhong, JIN Er.
Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer
[J]. Basic & Clinical Medicine, 2023, 43(9): 1457-1461.
|
| [13] |
LI Zhen, DUAN Zhaojun, LUO Yunping.
Ganglioside GD2 is a potential candidate marker for lung cancer stem cells
[J]. Basic & Clinical Medicine, 2023, 43(5): 777-784.
|
| [14] |
XUE Jianchao, WANG Yadong, LI Bowen, LIU Xinyu, LIANG Naixin, LI Shanqing.
Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer
[J]. Basic & Clinical Medicine, 2023, 43(3): 514-518.
|
| [15] |
YANG Ye, DANG Rong-guang, ZHANG Jing, DONG Chao, SONG Xue-jing.
Correlation of expression of lncRNA ZFAS1 and hsa-miR-372-3p in lung cancer tissues with the malignant characteristics and prognosis of patients
[J]. Basic & Clinical Medicine, 2022, 42(12): 1861-1866.
|